Clinical trial
Multicentre, Phase II Clinical Study of Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML
NCT07304232 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicentre, Phase II Clinical Study of Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- September 1, 2025
- Completion date
- December 31, 2028
- Enrollment
- 134 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
allogeneic hematopoietic cell transplantation (hct), aml (acute myeloid leukemia)